Zhen Y Cheng from Elk Grove, CA, age 42

Us Patents

Agents For Preventing And Treating Disorders Involving Modulation Of The Ryr Receptors
view source
US Patent:

7704990, Apr 27, 2010
Filed:

Aug 25, 2005
Appl. No.:

11/212413
Inventors:

Donald W. Landry - New York NY, US
Shixian Deng - White Plains NY, US
Zhen Zhuang Cheng - Elmhurst NY, US
Assignee:

The Trustees of Columbia University in the City of New York - New York NY
International Classification:

C07D 281/02
A61K 31/554
US Classification:

51421105, 51421109, 540490, 540552
Abstract:

The present invention provides novel compounds of Formula I.

Anti-Arrhythmic And Heart Failure Drugs That Target The Leak In The Ryanodine Receptor (Ryr2) And Uses Thereof
view source
US Patent:

7718644, May 18, 2010
Filed:

Mar 25, 2004
Appl. No.:

10/809089
Inventors:

Andrew Robert Marks - Larchmont NY, US
Donald W. Landry - New York NY, US
Shixian Deng - White Plains NY, US
Zhen Zhuang Cheng - Elmhurst NY, US
Assignee:

The Trustees of Columbia University in the City of New York - New York NY
International Classification:

A01N 43/00
A61K 31/00
US Classification:

51421105, 540552
Abstract:

The present invention provides methods for limiting or preventing a decrease in the level of RyR2-bound FKBP12. 6 in a subject. The present invention further provides methods for treating and preventing atrial and ventricular cardiac arrhythmias, heart failure, and exercise-induced sudden cardiac death in a subject. Additionally, the present invention provides use of JTV-519 in a method for limiting or preventing a decrease in the level of RyR2-bound FKBP12. 6 in a subject who has, or is a candidate for, atrial fibrillation. Also provided are uses of 1,4-benzothiazepine derivatives in methods for treating and preventing atrial and ventricular cardiac arrhythmias and heart failure in a subject, and for preventing exercise-induced sudden cardiac death. The present invention also provides methods for identifying agents for use in treating and preventing atrial fibrillation and heart failure, and agents identified by these methods.

Probes For In Vivo Targeting Of Active Cysteine Proteases
view source
US Patent:

8343458, Jan 1, 2013
Filed:

Apr 3, 2009
Appl. No.:

12/418116
Inventors:

Matthew S. Bogyo - Redwood City CA, US
Galia Blum - Jerusalem, IL
Alicia Berger - San Francisco CA, US
Zhen Cheng - Stanford CA, US
Sanjiv S. Gambhir - Stanford CA, US
Assignee:

The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA
International Classification:

A61K 51/00
A61M 36/14
US Classification:

424 169, 424 111, 424 165, 424 91, 424 93, 424 934, 424 94
Abstract:

Activity-based probes, which are specific for certain active cysteine proteases (caspase, cathepsin and legumain) and carry radioactive labels, are disclosed. The present probes comprise an acyloxymethyketone (AOMK) “warhead” that binds only to active enzyme. The probes further comprise peptide-like structure that targets the probe to a specific cysteine protease or protease family, and a radiolabel on the probe, which is bound to the targeted enzyme. It has been found that the present probes are stable in vivo and give specific target images distinguishable over background. The preferred probes are labeled with a positron-emitting agent such as Cu, I (SPECT) and Tc (PET). The probes show in vivo half-life and stability well suited for imaging.

Compounds And Methods For Treating And Preventing Exercise-Induced Cardiac Arrhythmias
view source
US Patent:

20040229781, Nov 18, 2004
Filed:

Oct 7, 2003
Appl. No.:

10/680988
Inventors:

Andrew Marks - Larchmont NY, US
Donald Landry - New York NY, US
Shi Deng - White Plains NY, US
Zhen Cheng - Elmhurst NY, US
International Classification:

A61K038/17
US Classification:

514/012000
Abstract:

The present invention provides a method for limiting or preventing a decrease in the level of RyR2-bound FKBP12.6 in a subject, a method for treating or preventing exercise-induced cardiac arrhythmia in a subject, and a method for preventing exercise-induced sudden cardiac death in a subject. Also provided are uses of JTV-519 in these methods. The present invention further provides methods for identifying agents for use in preventing exercise-induced sudden cardiac death, as well as agents identified by such methods. Also provided are methods for preventing exercise-induced sudden cardiac death by administering these agents. Additionally, the present invention provides methods for synthesizing JTV-519, radio-labeled JTV-519, and 1,4-benzothiazepine intermediates and derivatives.

Novel Anti-Arrythmic And Heart Failure Drugs That Target The Leak In The Ryanodine Receptor (Ryr2)
view source
US Patent:

20050186640, Aug 25, 2005
Filed:

Mar 23, 2005
Appl. No.:

11/088123
Inventors:

Andrew Marks - Larchmont NY, US
Donald Landry - New York NY, US
Shi Deng - White Plains NY, US
Zhen Cheng - Elmhurst NY, US
International Classification:

G01N033/53
G01N033/567
US Classification:

435007200
Abstract:

The present invention provides novel 1,4-benzothiazepine intermediates and derivatives, methods for synthesizing same, and methods for assaying same. The present invention also provides methods for using these novel compounds to limit or prevent a decrease in the level of RyR2-bound FKBPl2.6 in a subject; to prevent exercise-induced sudden cardiac death in a subject; and to treat or prevent heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia in a subject. The present invention further provides methods for identifying an agent that enhances binding of RyR2 and FKBP12.6, and agents identified by these methods. Additionally, the present invention provides methods for identifying agents for use in treating or preventing heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia, and in preventing exercise-induced sudden cardiac death. Also provided are agents identified by such methods.

Novel Anti-Arrythmic And Heart Failure Drugs That Target The Leak In The Ryanodine Receptor (Ryr2)
view source
US Patent:

20050187386, Aug 25, 2005
Filed:

Mar 23, 2005
Appl. No.:

11/088058
Inventors:

Andrew Robert Marks - Larchmont NY, US
Donald Landry - New York NY, US
Shi Xian Deng - White Plains NY, US
Zhen Zhuang Cheng - Elmhurst NY, US
International Classification:

C07D267/02
US Classification:

540546000
Abstract:

The present invention provides novel 1,4-benzothiazepine intermediates and derivatives, methods for synthesizing same, and methods for assaying same. The present invention also provides methods for using these novel compounds to limit or prevent a decrease in the level of RyR2-bound FKBP12.6 in a subject; to prevent exercise-induced sudden cardiac death in a subject; and to treat or prevent heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia in a subject. The present invention further provides methods for identifying an agent that enhances binding of RyR2 and FKBP12.6, and agents identified by these methods. Additionally, the present invention provides methods for identifying agents for use in treating or preventing heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia, and in preventing exercise-induced sudden cardiac death. Also provided are agents identified by such methods.

Novel Agents For Preventing And Treating Disorders Involving Modulation Of The Ryr Receptors
view source
US Patent:

20060194767, Aug 31, 2006
Filed:

Aug 25, 2005
Appl. No.:

11/212309
Inventors:

Andrew Marks - Larchmont NY, US
Donald Landry - New York NY, US
Shixian Deng - White Plains NY, US
Zhen Cheng - Elmhurst NY, US
Stephan Lehnart - New York NY, US
Assignee:

THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK - New York NY
International Classification:

A61K 31/675
A61K 31/655
C07D 291/08
C07D 417/02
US Classification:

514081000, 514211090, 514151000, 540552000
Abstract:

The present invention provides novel compounds of Formula I and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells. Such disorders and diseases include, by way of example only, cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. Cardiac disorder and diseases include, but are not limited to, irregular heartbeat disorders and diseases; exercise-induced irregular heartbeat disorders and diseases; sudden cardiac death; exercise-induced sudden cardiac death; congestive heart failure; chronic obstructive pulmonary disease; and high blood pressure. Irregular heartbeat disorders and diseases include and exercise-induced irregular heartbeat disorders and diseases include, but are not limited to, atrial and ventricular arrhythmia; atrial and ventricular fibrillation; atrial and ventricular tachyarrhythmia; atrial and ventricular tachycardia; catecholaminergic polymorphic ventricular tachycardia (CPVT); and exercise-induced variants thereof. Skeletal muscular disorder and diseases include, but are not limited to, skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. Cognitive disorders and diseases include, but are not limited to, Alzheimer's Disease, forms of memory loss, and age-dependent memory loss.

Compounds For Tissue Imaging And Methods Of Use Thereof
view source
US Patent:

20060280687, Dec 14, 2006
Filed:

Mar 17, 2006
Appl. No.:

11/378988
Inventors:

Zhen Cheng - Mountain View CA, US
Sanjiv Gambhir - Portola Valley CA, US
International Classification:

A61K 49/00
C07D 403/02
C07H 5/06
US Classification:

424009600, 536018700, 548427000, 536055300, 536053000
Abstract:

Briefly described, embodiments of this disclosure include cyanine/glucose compounds, methods of use, methods of imaging tissue, methods of imaging precancerous tissue, cancer, and tumors, methods of treating precancerous tissue, cancer, and tumors, methods of diagnosing precancerous tissue, cancer and tumors, methods of monitoring the progress of precancerous tissue, cancer and tumors, and the like.